Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 7, 2019
Daily News
November 7, 2019
- As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Zolgensma Not on Roster for Nov. 13 MHLW Panel Review
November 7, 2019
- 3rd Conditional Approval Candidate Was DMD Drug Viltolarsen, Nippon Shinyaku Reveals
November 7, 2019
- Takeda Acquires Rights to CAR NK Cell Therapies from MD Anderson
November 7, 2019
- Takeda Opens New Dengue Vaccine Manufacturing Facility in Germany
November 7, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…